An expanded access protocol for gemtuzumab ozogamicin gathered only safety data, no efficacy data, limiting insights into real-world use.
The management of CLL, including delays in work-up and treatment, and modifications to clinical trials, have been implemented across Italy in response to the COVID-19 pandemic.
Flow cytometry may provide an efficient, sensitive, and specific tool for the differential diagnosis of breast implant–associated ALCL, but a cell block may be able to answer additional questions about the disease.
Although numerous clinical studies have aimed to treat AML, most results have been disappointing, according to authors of a publication in Blood.
A retrospective study of CMV-seropositive adults receiving allogeneic HCT and CMV-seronegative HLA-matched sibling donors found that vancomycin exposure before HCT increased the risk for CMV reactivation.
Upon starting methotrexate treatment, LDH and albumin levels may be signals for AKIs in patients with hematologic malignancies.
VTE risk up with chemotherapy, radiation therapy; major bleeding risk up with PE, proximal DVT.
Patients with chronic lymphocytic leukemia who are treated with ibrutinib may have a higher incidence of atrial fibrillation than previously thought.
For pediatric high-risk B-cell NHL, adding rituximab to standard LMB chemotherapy prolongs event-free and overall survival but may increase adverse events.
A study compared the effects of intrathecal triple therapy to intrathecal methotrexate on disease-free survival among patients with B-ALL.
For patients with GVHD, ruxolitinib improves efficacy outcomes compared with 9 other commonly used options.
A study suggested that the immunotherapy could be sensitizing non-Hodgkin lymphoma patients to subsequent therapies.
The FDA has granted accelerated approval of Xpovio® (selinexor; Karyopharm) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy.
An assay from Mayo Clinic researchers screens multiple myeloma drugs to see how cells with different biomarkers and pretreatment histories react.
Tazverik, a methyltransferase inhibitor, is already indicated for the treatment of patients aged ≥16 years with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.
A recent small study is hypothesis generating and highlights the need for COVID-19-related studies with large cohorts of CLL patients.
Few population-based studies have compared treatment approaches in the setting of mantle cell lymphoma.
The addition of venetoclax to azacitidine was associated with a 34% reduction in risk of death.
The majority of patients enrolled in this phase 3 trial had previously received both a proteasome inhibitor and an immunomodulatory agent.
Despite thromboprophylaxis, patients who have newly developed multiple myeloma are at an “unacceptably high VTE risk”, study results suggest.